Filing Details

Accession Number:
0001209191-15-058197
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-01 18:09:52
Reporting Period:
2015-06-30
Filing Date:
2015-07-01
Accepted Time:
2015-07-01 18:09:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1269021 Portola Pharmaceuticals Inc PTLA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1574558 William Lis C/O Portola Pharmaceuticals, Inc.
270 East Grand Ave.
South San Francisco CA 94080
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-30 15,000 $7.00 15,000 No 4 M Direct
Common Stock Disposition 2015-06-30 5,400 $44.03 9,600 No 4 S Direct
Common Stock Disposition 2015-06-30 9,600 $44.73 0 No 4 S Direct
Common Stock Acquisiton 2015-07-01 15,000 $7.00 15,000 No 4 M Direct
Common Stock Disposition 2015-07-01 14,900 $45.54 100 No 4 S Direct
Common Stock Disposition 2015-07-01 100 $46.07 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-06-30 15,000 $0.00 15,000 $7.00
Common Stock Stock Option (Right to Buy) Disposition 2015-07-01 15,000 $0.00 15,000 $7.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
64,386 2012-03-08 2022-03-08 No 4 M Direct
49,386 2012-03-08 2022-03-08 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2015.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.44 to $44.43, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3), (4), and (5) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.44 to $45.17, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.94 to $45.89, inclusive.
  5. These shares were sold in a single transaction at a price of $46.07.